← Leaderboards
Xiuling Lu
University Of Connecticut Storrs
$818,826
Attributed
$818,826
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $348.7K · FY2014–19$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
Funding mix
By agency
FDA$435,880 · 1
NIH$382,946 · 2
By mechanism
U01$435,880 · 1
R41$224,946 · 1
R03$158,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryPenetrationImageIrradiationNeoplasm MetastasisParticleDoseHolmiumIntraperitonealIntravenousAnimalsNanoparticleNeutronsChemotherapyChemotherapeutic AgentClinical TrialsGreater Sac Of PeritoneumBrachytherapyAnimal ModelCellsCancer PatientBaseCause Of DeathPeritoneal
Grant awards (5)
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases$224,946
R41 · FY2019 · CA · contact PI
Intraperitoneal Delivery of Targeted Nanoparticles for Metastatic Ovarian Cancer$79,000
R03 · FY2016 · CA · contact PI
Dissolution Methods for Predicting Bioequivalence of Ocular Semi-Solid Formulations$87,175
U01 · FY2015 · FD · contact PI
Intraperitoneal Delivery of Targeted Nanoparticles for Metastatic Ovarian Cancer$79,000
R03 · FY2015 · CA · contact PI
Dissolution Methods for Predicting Bioequivalence of Ocular Semi-Solid Formulations$348,705
U01 · FY2014 · FD · contact PI